|Bid||146.01 x 800|
|Ask||145.93 x 900|
|Day's Range||145.57 - 147.67|
|52 Week Range||109.16 - 157.00|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||25.70|
|Forward Dividend & Yield||4.04 (2.78%)|
|Ex-Dividend Date||Aug. 24, 2020|
|1y Target Est||N/A|
Johnson & Johnson announced that its coronavirus vaccine candidate had entered the pivotal human trial phase that will enroll up to 60,000 participants worldwide.
Wall Street's main indexes fell on Wednesday as data showed domestic business activity slowed in September, although a record high for Nike following a strong quarterly earnings report capped declines on the blue-chip Dow. "There's a lot of uncertainties out there, not the least of which is the election, what stimulus can potentially look like and if an increase in COVID-19 cases leads to more restrictions," said Lindsey Bell, chief investment strategist at Ally Invest in Charlotte, North Carolina.
Johnson & Johnson's rapid progress on its coronavirus vaccine is weighing on the biotech's shares today.